check_circleStudy Completed

Neoplasms

Phase Ib study of PI3(phosphoinositol 3)-Kinase inhibitor Copanlisib with MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766) in patients with advanced cancer

Trial purpose

The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766)have both been tested as single agent treatments in other phase I studies. This study will test the combination of these two drugs to try and answer the following questions:
1. What are the side effects of the combination of Copanlisib and Refametinib (BAY86-9766)when given together at different/increasing dose levels?
2. What dose level of Copanlisib and Refametinib (BAY86-9766) should be tested in future clinical research studies?
3. How much Copanlisib is in the blood at specific times after administration and does adding Refametinib (BAY86-9766) have an affect?
4. How much Refametinib (BAY86-9766) is in the blood at specific times after administration and does adding Copanlisib have an affect?
5. Does the combination of Refametinib (BAY86-9766) and Copanlisib have an effect on tumors?

Key Participants Requirements

Sex

Both

Age

18 - N/A

Trial summary

Enrollment Goal
64
Trial Dates
July 2011 - April 2014
Phase
Phase 1
Could I Receive a placebo
No
Products
Aliqopa (Copanlisib, BAY80-6946)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Klinik für Tumorbiologie FreiburgFreiburg, 79106, Germany
Completed
Erasmus Medisch CentrumROTTERDAM, 3015 CE, Netherlands
Active, not recruiting
University of Texas MD Anderson Cancer CenterHouston, 77030, United States
Completed
Shea Medical CenterScottsdale, 85260, United States
Completed
Tyler Cancer CenterTyler, 75702, United States
Completed
Northwest Cancer Specialists, PCVancouver, 98684, United States
Completed
Comprehensive Cancer Centers of NevadaLas Vegas, 89169, United States
Completed
Greenville Health SystemGreenville, 29605, United States

Primary Outcome

  • Maximum Tolerated Dose
    date_rangeTime Frame:
    2 years
    enhanced_encryption
    Safety Issue:
    Yes
  • Comparison of the Copanlisib AUC when given alone with the AUC when given with Refametinib (BAY86-9766)
    date_rangeTime Frame:
    At day 15
    enhanced_encryption
    Safety Issue:
    No
  • Comparison of the Refametinib (BAY86-9766) AUC when given alone with the AUC when given with Copanlisib
    date_rangeTime Frame:
    At day 15
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Tumor Response as measured by RECIST 1.1 criteria
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    No
  • Biomarker evaluation including analysis of pathway activation in blood and plasma
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    No
  • Tumor Response as measured by FDG-PET at MTD and expansion cohort(s)
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    No
  • Pharmacodynamic biomarker evaluation analysis using paired tumor biopsies
    date_rangeTime Frame:
    3 years
    enhanced_encryption
    Safety Issue:
    No

Trial design

Phase Ib trial of the combination of PI3K inhibitor BAY 80-6946 and allosteric-MEK inhibitor BAY 86-9766 in subjects with advanced cancer
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1